%0 Journal Article
%T Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future
%A Juan J. Garcia-Vallejo
%A Sanne Duinkerken
%A Yvette van Kooyk
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2016.1214791
%X Glioblastoma multiforme (GBM) is the most aggressive brain tumor and median survival time with current therapies is only 14.6 mo. Although multiple immunotherapeutic strategies are being explored, efficacy remains poor. In order to improve immunotherapy for GBM, we propose to combine currently used endogenous with human cytomegalovirus (HCMV) specific antigens expressed on cancer cells
%K C-type lectin receptor
%K dendritic cell
%K glioblastoma
%K HCMV
%K immunotherapy
%K vaccination
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048761/